What is William Blair’s Estimate for VIGL Q1 Earnings?

Vigil Neuroscience, Inc. (NASDAQ:VIGL) – Equities researchers at William Blair issued their Q1 2026 earnings per share (EPS) estimates for Vigil Neuroscience in a research note issued to investors on Thursday, March 13th. William Blair analyst S. Schram forecasts that the company will earn $0.49 per share for the quarter. William Blair has a “Outperform” rating on the stock. The consensus estimate for Vigil Neuroscience’s current full-year earnings is ($2.07) per share. William Blair also issued estimates for Vigil Neuroscience’s Q2 2026 earnings at ($0.51) EPS, Q3 2026 earnings at ($0.54) EPS, Q4 2026 earnings at ($0.57) EPS and FY2026 earnings at ($2.12) EPS.

Vigil Neuroscience (NASDAQ:VIGL) last posted its quarterly earnings data on Thursday, March 13th. The company reported ($0.57) earnings per share for the quarter, missing the consensus estimate of ($0.49) by ($0.08).

Several other brokerages have also commented on VIGL. HC Wainwright cut their target price on Vigil Neuroscience from $17.00 to $14.00 and set a “buy” rating on the stock in a research report on Friday. Wedbush cut their price target on Vigil Neuroscience from $24.00 to $13.00 and set an “outperform” rating on the stock in a report on Friday. JMP Securities reaffirmed a “market outperform” rating and set a $22.00 price target on shares of Vigil Neuroscience in a research report on Tuesday, November 26th. Finally, Guggenheim reaffirmed a “buy” rating on shares of Vigil Neuroscience in a research report on Friday, January 24th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $16.25.

Vigil Neuroscience Trading Down 2.0 %

Shares of VIGL opened at $1.98 on Monday. The firm’s fifty day simple moving average is $2.34 and its two-hundred day simple moving average is $2.77. Vigil Neuroscience has a 12 month low of $1.49 and a 12 month high of $6.06. The stock has a market capitalization of $80.94 million, a P/E ratio of -0.96 and a beta of 1.82.

Hedge Funds Weigh In On Vigil Neuroscience

Several institutional investors have recently bought and sold shares of VIGL. Woodline Partners LP increased its position in Vigil Neuroscience by 239.1% in the fourth quarter. Woodline Partners LP now owns 488,756 shares of the company’s stock worth $831,000 after buying an additional 344,614 shares during the last quarter. Squarepoint Ops LLC purchased a new stake in Vigil Neuroscience in the 4th quarter worth about $193,000. Two Sigma Advisers LP raised its stake in Vigil Neuroscience by 243.8% in the 4th quarter. Two Sigma Advisers LP now owns 69,100 shares of the company’s stock valued at $117,000 after acquiring an additional 49,000 shares during the period. Two Sigma Investments LP lifted its holdings in Vigil Neuroscience by 44.0% during the fourth quarter. Two Sigma Investments LP now owns 136,920 shares of the company’s stock valued at $233,000 after purchasing an additional 41,836 shares during the last quarter. Finally, Trustees of Columbia University in the City of New York bought a new position in Vigil Neuroscience during the fourth quarter worth about $328,000. Hedge funds and other institutional investors own 83.64% of the company’s stock.

About Vigil Neuroscience

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.